CORRECTION FROM SOURCE: Wellgistics Health Secures $50M ELOC Facility for XRP Treasury Reserve and Real-Time Payments Infrastructure and Other General Ops
The correction is to the headline only
TAMPA, FL / ACCESS Newswire / May 8, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX), a technology-first pharmaceutical distribution and healthcare infrastructure company, today announced a new initiative to pioneer the use of XRP, a blockchain-based digital asset, as both a treasury reserve and a real-time payments infrastructure-which management believes, upon successful commercialization, would make Wellgistics among the first publicly traded healthcare companies to deploy XRP in this manner.
This XRP payment initiative is supported by Wellgistics Health's $50 million Equity Line of Credit (ELOC), the proceeds of which may be utilized to further develop and unlock programmable liquidity and on-demand financial infrastructure designed to eliminate banking delays, reduce cost, and increase transparency across its national healthcare network.
"At Wellgistics Health, we challenge the idea that healthcare has to be tethered to legacy systems, bloated intermediaries, and slow-moving money," said Brian Norton, CEO of Wellgistics Health. "We are developing a platform that connects manufacturers directly to pharmacies and patients-bypassing the red tape and placing control back in the hands of those who deliver care. Our blockchain-enabled payment system and ledger is just the next logical step in healthcare evolution, allowing us to hardwire speed, liquidity, and transparency into a system that's long been starved of all three. I believe that the future winners in healthcare won't be the companies with the biggest buildings…they'll be those with the fastest rails, cleanest data, and most efficient platforms. We're betting on infrastructure…not inertia."
Why XRP? Why Now?
We believe that there are certain advantages to integrating XRP and its related infrastructure into its healthcare ecosystem. These include, among others:
Speed: XRP settles transactions in 3-5 seconds vs. 1-3 days for ACH or wire transfers, allowing for near real-time settlement among pharmacies, suppliers, and manufacturers.Cost: Less than $0.0002 per transfer vs. $10-$30 for standard bank wires.Transparency: All transactions are logged on the XRP Ledger for real-time compliance, rebate tracking, and auditability.Scope: Supports global vendor payouts with significantly low foreign exchange and wire transfer fees.Flexibility: Allows for XRP-backed lines of credit to support independent pharmacy liquidity.
These benefits will support faster vendor payments, performance-based rebates, and embedded liquidity tools for pharmacies and manufacturers in the Wellgistics ecosystem.
Use Cases Across the Ecosystem
Real-time settlement between pharmacies, suppliers, and manufacturersSmart rebates calculated automatically based on real-world dataXRP-backed credit lines to enhance liquidity for independent pharmaciesGlobal vendor payouts with near-zero foreign transaction and wire costsImmutable compliance layer supporting DSCSA reporting and pricing validation
"We're working to unlock capital velocity with surgical precision," said Mark DiSiena, CFO of Wellgistics Health. "We believe that our XRP-powered infrastructure will allow us to run leaner, faster, and with more control than any of our peers in pharma infrastructure."
The Market Is Moving-And Wellgistics Intends to Lead
XRP is gaining momentum across global institutions, as demonstrated by the following:
CME Group to launch XRP futures for institutional access→ CME will launch cash-settled XRP futures contracts in May 2025 to meet rising institutional demand.¹Mastercard identifies XRP as a bridge currency for cross-border payments→ Mastercard's 2025 report highlights XRP as a top solution for global remittances and cost efficiency.²Ripple acquires prime brokerage firm Hidden Road for $1.25B→ This landmark acquisition expands XRP's footprint in institutional liquidity and asset servicing.³Ripple receives regulatory licensing in Dubai→ Ripple became the first blockchain payment provider licensed by the DFSA to operate crypto-based financial services in the UAE.⁴Ripple expands real-world cross-border payment corridors in Brazil and Portugal→ Ripple now enables live XRP-powered remittances between LATAM and Europe through its partnership with Unicâmbio.⁵
"Others are waiting for change. We're building it," Norton added. "I strongly believe that our XRP initiative positions Wellgistics Health years ahead of the curve-and squarely at the center of where healthcare and fintech converge."
About Wellgistics Health
Wellgistics Health, Inc. (NASDAQ:WGRX) is a publicly traded healthcare infrastructure company transforming how medications move, get priced, and reach patients. The company operates across pharmaceutical distribution, prescription technology, and clinical fulfillment-connecting over 150 direct manufacturer contracts to a growing network of more than 6,000 independent pharmacies nationwide.
Wellgistics Health delivers real-time prescription hub services, compliance-driven logistics, and patient-first fulfillment models, while equipping pharmacies with embedded financial, clinical, and digital tools. Its integrated platform supports a wide range of therapeutic categories-from specialty-lite to maintenance meds-by eliminating friction, accelerating reimbursements, and creating direct, transparent pathways between manufacturers, providers, pharmacies, and patients.
For more information, visit: www.wellgisticshealth.com.
Forward-Looking Statements
This press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, Wellgistics Health's statements regarding Wellgistics Health's strategy and descriptions of its future operations, prospects, and plans. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from Wellgistics Health's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other risks detailed in our reports and statements filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in Wellgistics Health's filings with the SEC, which are available for review at www.sec.gov.
Media Contact: media@wellgisticshealth.comInvestor Relations: investors@wellgisticshealth.com
References
CME Group Press Release: CME to Launch XRP FuturesAInvest: Mastercard Identifies XRP as Bridge CurrencyReuters: Ripple Acquires Hidden Road for $1.25BBusinessWire: Ripple Licensed by DFSA in DubaiPYMNTS: Ripple Launches Portugal-Brazil Corridor
SOURCE: Wellgistics Health, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
38 minutes ago
- Business Insider
Upcoming Stock Splits This Week (June 9 to June 13)
These are the upcoming stock splits for the week of June 9 to June 13, based on TipRanks' Stock Splits Calendar. A stock split is a corporate maneuver that increases the number of shares outstanding by issuing more shares to existing holders, all while keeping the company's total market value unchanged. This lowers the price per share, often making the stock more affordable and potentially more appealing to retail investors. Confident Investing Starts Here: In contrast, a reverse stock split reduces the number of shares by consolidating them, which raises the price per share without affecting the company's valuation. Companies typically turn to this strategy to meet stock exchange requirements – like Nasdaq's minimum price threshold – and avoid delisting. Whether intended to boost investor interest or maintain compliance with exchange rules, these adjustments often serve as key signals for traders tracking a company's strategic direction. Let's take a look at the upcoming stock splits for the week. Nektar Therapeutics (NKTR) – Nektar Therapeutics is a biopharmaceutical company developing novel drug candidates. Following stockholder approval on May 23, the company formalized a 1-for-15 reverse stock split. The split takes effect on June 8, with trading on a split‑adjusted basis beginning June 9. Fangdd Network Group (DUO) – China-based Fangdd is a technology-driven real estate platform. The company confirmed a 16-for-1 reverse share consolidation, effective June 9, aimed at boosting its share price and maintaining compliance with listing standards. Bone Biologics (BBLG) – Bone Biologics develops orthobiologic products for spinal fusion procedures. After gaining shareholder approval on May 30, the company filed for a 1-for-6 reverse stock split, which takes effect on June 10. The goal is to elevate its share price back into compliance with Nasdaq's minimum pricing rules and enhance its appeal to institutional investors. Cero Therapeutics Holdings (CERO) – Cero Therapeutics is a biotech firm developing engineered T-cell immunotherapies for cancer. Following shareholder approval in November and board action on December 25, it enacted a 1-for-100 reverse stock split effective on January 8, consolidating every 100 shares into one. The move aimed to boost the stock above $1.00 and secure compliance with Nasdaq's listing standards. Inuvo, Inc. (INUV) – Inuvo specializes in AI-powered marketing technologies and is gearing up for a 1-for-10 reverse stock split on June 10. The move is designed to lift its share price, restore Nasdaq compliance, and strengthen its financial foundation for future growth. O'Reilly Automotive (ORLY) – O'Reilly Automotive is a specialty retailer of automotive aftermarket parts and accessories. On March 13, the company declared a 15-for-1 forward stock split, with the distribution of additional shares set for June 9 and split-adjusted trading beginning June 10. SaverOne 2014 (SVRE) – Israel-based SaverOne develops driver safety systems that block mobile-device distractions in vehicles. The company executed a 1-for-3 reverse ADS split, effective June 11, adjusting its American Depositary Share ratio to strengthen its Nasdaq standing and enhance market appeal. China Natural Resources, Inc. (CHNR) – China Natural Resources is focused on mining exploration in Inner Mongolia and is working toward picking up Zimbabwe's Williams Minerals lithium mine for up to $1.75 billion. The company executed an 8-for-1 reverse stock split effective June 12 to meet Nasdaq's $1 minimum bid price requirement, converting every eight shares into one to boost its per-share value and comply with listing rules
Yahoo
2 hours ago
- Yahoo
Ituran Location and Control Ltd (ITRN) Q1 2025 Earnings Call Highlights: Record Revenue and ...
Revenue: $86.5 million, a 2% increase year-over-year. Subscription Fees Revenue: $62.2 million, a 2% increase year-over-year. Product Revenue: $24.3 million, a 1% increase year-over-year. EBITDA: $23.3 million, 26.9% of revenues, a 4% increase year-over-year. Net Income: $14.6 million, or $0.73 diluted earnings per share, a 12% increase year-over-year. Operating Cash Flow: $15.5 million for the first quarter. Subscriber Base: Increased by 99,000 to 2,508,000. Dividend: $10 million declared for the quarter, representing $0.50 per share. Net Cash: $75.7 million as of March 31, 2025. Warning! GuruFocus has detected 4 Warning Signs with MOV. Release Date: May 28, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Ituran Location and Control Ltd (NASDAQ:ITRN) achieved a significant milestone by surpassing 2.5 million subscribers, driven by a net addition of 99,000 subscribers in the first quarter. The company signed a new telematics service agreement with Stellantis, a major car OEM manufacturer, contributing to the subscriber growth. First-quarter revenues reached a record $86.5 million, marking a 2% increase year-over-year, with a 7% growth in local currency terms. EBITDA for the quarter increased by 4% to $23.3 million, with a 12% growth in local currency terms. Ituran Location and Control Ltd (NASDAQ:ITRN) declared a $10 million dividend for the quarter, reflecting strong profitability and cash flow, with an annualized dividend yield of around 6%. The strengthening of the US dollar negatively impacted financial results when translated from local currencies, particularly affecting revenues from Brazil and Mexico. The new OEM agreement with Stellantis, while contributing to subscriber growth, involves lower ARPU compared to the company's average. Increased R&D and marketing expenditures outpaced revenue growth, raising concerns about cost management. CapEx was higher than average in Q1, with expectations for it to decrease in subsequent quarters, indicating potential volatility in capital expenditures. The insurance market in Latin America, particularly in Brazil and Mexico, shows limited short-term potential for usage-based insurance (UBI) solutions, impacting growth opportunities in this segment. Q: In terms of new agreements, does it imply you set up new equipment and provide services for each produced car by Stellantis in Latin America, or do you have some options for them? A: Eyal Sheratzky, Co-CEO, explained that the current agreement with Stellantis is to provide services based on existing technology in their cars. While there is potential to broaden the relationship and add other services or hardware in the future, the current focus is on service provision. Q: What primarily affected the ramp-up of your subscription base, given the recent increase to roughly 100,000 per quarter? A: Eyal Sheratzky noted that the agreement with Stellantis initially brought a bulk of car owners to Ituran, which is not typical. Future quarters are expected to return to the usual rate of about 40,000 new subscribers per quarter. Q: Has Ituran taken steps to improve product gross margins, and what should we expect for the next couple of quarters? A: Eli Kamer, CFO, stated that the improvement in gross margins is due to operational leverage and cost savings. While telematics services margins are expected to improve with subscriber growth, product margins may fluctuate due to product mix changes. Q: What are your expectations for the Latin American insurance market, particularly regarding UBI insurance? A: Eyal Sheratzky mentioned that while there is high demand for car theft solutions in Brazil, the insurance companies in Brazil and Mexico are not yet ready to adopt UBI solutions. However, Argentina has shown some interest, and Ituran is prepared to capitalize on future opportunities. Q: Can you discuss the dynamics in the market for product revenues and how you see the pipeline evolving throughout the year? A: Eli Kamer explained that product revenue pipelines are managed on a daily basis, with stock levels adjusted according to demand. Gross margins for product revenues are expected to remain around 20-25%, depending on the product mix. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
3 hours ago
- Yahoo
Down 48% From Its Peak, Is This Market-Crushing Growth Stock a Buy Now?
Lululemon tumbled 20% on its recent earnings report. The company slashed its profit guidance due to pressure from tariffs. After the sell-off, the growth stock looks well priced at a forward P/E of 18. 10 stocks we like better than Lululemon Athletica Inc. › Lululemon athletica (NASDAQ: LULU) might not have the profile of a traditional market-crushing stock, but it's been one of the best-performing consumer-facing stocks of the last 20 years. More than any other company, Lululemon is responsible for making athleisure a massive apparel category, and it's made it one of the most valuable apparel companies in the world. Going back to its 2006 IPO, the stock is up roughly 1,800%, and even over the last decade, the stock has gained more than 300% as it's continued to deliver strong growth. However, more recently the stock has struggled. After peaking in late 2023, shares have fallen on concerns about its valuation, slowing growth, and now the trade war and the broader threat to the global economy. The stock is now down 48% from its peak. Lululemon tumbled in its first-quarter earnings report as comparable sales growth slowed to just 1% with comps down 2% in the Americas. Revenue in the quarter rose 7% to $2.37 billion as the company continues to open new stores, which matched estimates. Further down the income statement, gross margin improved from 57.7% to 58.3%, but operating income rose just 1% to $438.6 million as operating margin fell 110 basis points to 18.5% due to an increase in selling, general, and administrative expenses. On the bottom line, earnings per share increased from $2.54 to $2.60, which edged out the consensus of $2.59. What really pressured the stock was the company's guidance, due in part to the impact of tariffs as management said price hikes to absorb tariffs would be targeted and limited. For the full year, Lululemon maintained revenue guidance of $11.15 billion to $11.3 billion, or 6% revenue growth at the midpoint. However, it cut its full-year earnings-per-share guidance from $14.95-$15.15 to $14.58-$14.78. Second-quarter guidance also missed the mark. Lululemon's decision to maintain revenue guidance with a growth rate that's steady from the first quarter shows that it doesn't anticipate a significant impact on demand. Rather, the challenges the company is facing are on the cost side, primarily due to tariffs. The company now expects operating margin to fall 160 basis points, weighing on earnings per share. While Lululemon's growth has slowed in its core North American market, the company continues to see a long runway in China, which represents its biggest market for new store growth. In the first quarter, revenue in China increased 21% on 7% comparable sales growth, and China made up 13% of total revenue last year. Like other American consumer brands that have done well in China like Apple, Starbucks, and Nike, Lululemon seems to be benefiting from the same upscale brand reputation that those companies have as well as a culture of conspicuous consumption. Additionally, Lululemon has managed to deliver solid growth in China even as the consumer economy has been weak there. The retailer currently has 154 stores in China, 20% of its total, and it had an initial goal of opening 200 stores, though it now expects to top that. CFO Meghan Frank said, "We still feel we're early in our journey" in China on the earnings call. Lululemon's challenges with tariffs seem to be similar to what we've heard from other retailers in apparel and related sectors, so it shouldn't be a cause for alarm from investors. Meanwhile, the tariff situation is fluid enough that rates could easily change, and it's unclear if the tariffs will still be relevant a few years from now. After cutting its guidance for the year and Friday's sell-off, Lululemon now trades at a forward P/E of 18. For a company with its brand strength, historical growth rate, and a runway to expand in China, that looks like a great price. While investors may have to be patient as the trade war plays out, at the current price, Lululemon looks like a clear buy. Before you buy stock in Lululemon Athletica Inc., consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Lululemon Athletica Inc. wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Jeremy Bowman has positions in Nike and Starbucks. The Motley Fool has positions in and recommends Apple, Lululemon Athletica Inc., Nike, and Starbucks. The Motley Fool has a disclosure policy. Down 48% From Its Peak, Is This Market-Crushing Growth Stock a Buy Now? was originally published by The Motley Fool Sign in to access your portfolio
